Ad5-nCoV
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04552366 | Sep → Dec 2020 | COVID-19 | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Completed | No outcome recorded |
| Phase 1 | NCT04568811 | Sep → Oct 2020 | — | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1 | NCT04313127 | Mar 2020 → Jan 2021 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05043259 | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1/2 | NCT04840992 | Apr 2021 → Jul 2022 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04398147 | Aug 2020 → Dec 2021 | COVID-19 | CanSino Biologics Inc. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05293223 | Oct 2021 → Nov 2022 | — | Fundación Huésped | Completed | No outcome recorded |
| Phase 2 | NCT05005156 | Jun 2021 → Jan 2023 | COVID-19 | Fundación Huésped | Completed | No outcome recorded |
| Phase 2 | NCT04566770 | Sep 2020 → Sep 2021 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05442684 | Nov 2022 → Mar 2023 | COVID-19 | CanSino Biologics Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT05169008 | Feb 2022 → Jan 2023 | COVID-19 | CanSino Biologics Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05204589 | Jan → Apr 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT04526990 | Sep 2020 → Aug 2021 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04540419 | Sep 2020 → Jun 2021 | COVID-19 | NPO Petrovax | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05855408 | May 2023 → May 2024 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT05303584 | Apr → Jun 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04892459 | May → Jul 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05313646 | Mar → Apr 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05886790 | May → Dec 2023 | COVID-19 | Zhongnan Hospital | Unknown | No outcome recorded |
| — | NCT04916886 | Jun 2021 → Jul 2022 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04341389 Comparator | Apr → Nov 2020 | COVID-19 | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-nCoV | “BACKGROUND: To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 ×...” PMID 36888640 ↗ Mar 202316“450 participants were enrolled and randomly assigned into three groups to be vaccinated with an aerosolized Ad5-vectored bivalent vaccine (wild-type and BA.5, Ad5-CoV5T), an...” PMID 40775215 ↗ Aug 2025 “Eligible participants in Scale A were randomly assigned to receive the single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) of different scales at a...” PMID 37432025 ↗ Jan 2023 “This is a phase IIb clinical trial to evaluate safety and immuogenicity of Ad5-nCoV developed by Cansino and Beijing Institute of Biotechnology in health people aged 6 years...” NCT04566770 ↗ “The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies.” PMID 34953526 ↗ Dec 2021 “We aimed to assess the safety and immunogenicity of a homologous booster dose of the recombinant adenovirus type 5-vectored coronavirus disease 2019 (COVID-19) vaccine (Ad5-nCoV).” PMID 38038866 ↗ Dec 2023 “An orally aerosolized adenovirus type-5 vector-based coronavirus disease 2019 (COVID-19) vaccine (Ad5-nCoV) has recently been authorized for boosting immunization in China.” PMID 37202147 ↗ Sep 2023 “12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration” NCT04398147 ↗ “receiving Ad5-nCoV (intramuscular injection)” NCT05169008 ↗ |
| Known as | Ad5-nCoV vaccine | “Subjects are assigned to receive one dose of aerosolized Ad5-nCoV vaccine as the second booster.” NCT05855408 ↗ |
| Known as | Ad5-nCoV-IH | “heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV-IH) after two-dose priming with an inactivated SARS-CoV-2...” NCT05204589 ↗ |
| Known as | Ad5-nCoV/O | “Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster...” NCT05442684 ↗ |
| Known as | Ad5-nCoV/O-IH | “Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster...” NCT05442684 ↗ |
| Known as | aerosolised Ad5-nCoV | “BACKGROUND: Aerosolised Ad5-nCoV is one of the first licensed mucosal respiratory vaccine against SARS-CoV-2 in the world; however, the safety profile of this vaccine has not...” PMID 37352880 ↗ Jun 2023 |
| Known as | Aerosolized Ad5-nCoV | “Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc.” NCT05204589 ↗ |
| Known as | Convidecia | “We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac...” PMID 35087233 ↗ Jan 20221“Convidecia” NCT05313646 ↗ |
| Known as | recombinant adenovirus type-5 vectored COVID-19 vaccine | “Eligible participants in Scale A were randomly assigned to receive the single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) of different scales at a...” PMID 37432025 ↗ Jan 2023 |
| Known as | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | “Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)” NCT05005156 ↗ |
| Known as | Recombinant SARS-CoV-2 Ad5 vectored vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04892459 ↗ |
| Modality | Vaccine | “Ad5 vectored COVID-19 vaccine” PMID 32450106 ↗ May 2020 |
| Route | Intramuscular | “intramuscular injection of vaccine” PMID 32450106 ↗ May 2020 |